Naiz (nimesulid) incombined treatment of patients with chronic bacterial prostatitiswith chronic pelvic pain syndrome
- Authors: Neimark AI1, Yakovets Y.V1, Aliev RT1
-
Affiliations:
- Issue: No 5 (2004)
- Pages: 31-34
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/275560
- ID: 275560
Cite item
Full Text
Abstract
Naiz (nimesulid) was given to 46 patients (age 24-52 years) with
chronic abacterial prostatitis suffering from chronic pelvic pain syndrome
(CPPS) which appeared from 20 to 3 years before the treatment.
Microscopy of prostatic secretion showed normal count of leukocytes.
Transrectal ultrasound investigation with dopplerography has
found normal echostructure of the prostate but blood flow parameters
were subnormal. Naiz was given in a dose 100 mg (1 tablet) twice a
day for 15-20 days. The treatment relieved pain in 68-87% patients
(mean 77.5%). The control ultrasound investigation detected much
better circulation. Quality of life improved significantly. Side effects
were mild. The effect persisted for 3 months of the follow-up. Thus,
the addition of such nonsteroid antiinflammatory drug as naiz
(nimesulid) to treatment of patients with chronic abacterial prostatitis
is justified. The drug improves quality of life, induces side effects rarely
and can be used for a long time with a persistent efficacy.
chronic abacterial prostatitis suffering from chronic pelvic pain syndrome
(CPPS) which appeared from 20 to 3 years before the treatment.
Microscopy of prostatic secretion showed normal count of leukocytes.
Transrectal ultrasound investigation with dopplerography has
found normal echostructure of the prostate but blood flow parameters
were subnormal. Naiz was given in a dose 100 mg (1 tablet) twice a
day for 15-20 days. The treatment relieved pain in 68-87% patients
(mean 77.5%). The control ultrasound investigation detected much
better circulation. Quality of life improved significantly. Side effects
were mild. The effect persisted for 3 months of the follow-up. Thus,
the addition of such nonsteroid antiinflammatory drug as naiz
(nimesulid) to treatment of patients with chronic abacterial prostatitis
is justified. The drug improves quality of life, induces side effects rarely
and can be used for a long time with a persistent efficacy.
References
- Щетинин В. В., Колпинский Г. И., Зотов Е. А. Лечение хронического простатита. М: Медицина; 2002; 235.
- Сердюк И. Л. Новые перспективы развития противовоспалительной терапии. В кн.: Опыт применения препарата Найз в Российской Федерации. М.; 2002.
- Насонов Е. Л. Клин, фармакол. и тер. 1999; 1: 65-69.
- Шостак Н. А., Логинова Т. К. Современные представления о лечении ревматоидного артрита. В мире лекарств 2001; 2: 4-7.
- Brooks P., Emery P., Evans J. E. et al. Interpreting the clinical significance of the differential inhibition of cyclooxigenase-2. Rheumatology 1999; 38: 779-788.
- Сизова Л. В., Багирова Г. Г. Показатели качества жизни в оценке эффективности диклофенака и Найза® у больных гонартрозом. Оренбург: Изд-во Оренбург, гос. мед. акад.; 2002.
- Насонов Е. Л. Эффективность и переносимость нестероидного противовоспалительного средства Нимесулид: новые данные. Рус. мед. журн., 2001; 5: 636-639.
- Фармакоэкономические аспекты применения нимесулида (Найза). СПб.; 2003.
- Лоран О. Б., Сегал А. С. Урология 2001; 5: 16-19.
- Типовые клинические фармстатьи. Государственный реестр лекарственных средств. 2000; т. 2.
- Энциклопедия лекарств. Государственный реестр лекарственных средств России. 2002; вып. 9.
Supplementary files
